Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (3)
  • Open Access


    Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy

    Yue-shen Wang*1, Jing Tian†1, Yong Han, Shu-mei Han, Sheng-bin Shi

    Oncology Research, Vol.24, No.2, pp. 129-135, 2016, DOI:10.3727/096504016X14618564639213

    Abstract We evaluated the efficacy and feasibility of the combination of gemcitabine plus vinorelbine in patients with platinum-based chemotherapy-refractory esophageal cancer. We enrolled 35 patients who received gemcitabine plus vinorelbine as second-line treatment after platinum-based chemotherapy failure between May 2009 and April 2012. Dosage: gemcitabine 1,000 mg/m2 plus vinorelbine 25 mg/m2 ; all drugs were administered on days 1 and 8 of a 21-day cycle, and this was continued until failure or unacceptable toxicity. A total of 125 cycles of treatment were administered, and all patients received at least two cycles of treatment (two to five cycles;… More >

  • Open Access


    Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience

    Stefania Nobili*, Daniele Lavacchi, Gabriele Perrone*, Giulio Vicini, Renato Tassi‡1, Ida Landini*, AnnaMaria Grosso§, Giandomenico Roviello, Roberto Mazzanti, Carmine Santomaggio¶2, Enrico Mini

    Oncology Research, Vol.28, No.3, pp. 237-248, 2020, DOI:10.3727/096504019X15755437099308

    Abstract The use of vinorelbine as a single agent or in combination regimens in non-small cell lung cancer (NSCLC) is associated with satisfactory clinical activity. However, the role of vinorelbine-based chemotherapy in chemonaive locally advanced unresectable or metastatic NSCLC patients, according to real-world treatment patterns, has still not been widely explored. Eighty-one patients treated at a single institution were retrospectively analyzed. Thirty-seven received standard first-line single-agent vinorelbine, and 44 received vinorelbine plus platinum drugs, based on physician’s choice; 61.7% were older than 70 years, and 60.5% were affected by 2 comorbidities. Sixty-three patients were evaluable for… More >

  • Open Access


    A Real-World Study on Oral Vinorelbine for the Treatment of Metastatic Breast Cancer

    Jiayi Huang1, Xue Bai1, Xiaofeng Xie1, Liping Chen1, Xiaofeng Lan1, Qiuyi Zhang1, Lin Song1, Pengjiao Hong2,3, Caiwen Du1,*

    Oncologie, Vol.24, No.1, pp. 131-145, 2022, DOI:10.32604/oncologie.2022.019881

    Abstract Background: Vinorelbine can be used to treat metastatic breast cancer as a single agent or in combination with other chemotherapy agents, although there is little real-world data for its use, particularly the oral form, in China. The current study aimed to explore the efficacy and safety of oral vinorelbine in patients with metastatic breast cancer in real-world clinical practice. Methods: A total of 194 patients with metastatic breast cancer received oral vinorelbine as a treatment between February 2017 and January 2021 at the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese… More >

Displaying 1-10 on page 1 of 3. Per Page